- Home
- RARE vs GBDC Comparison
RARE vs GBDC Comparison
Compare RARE & GBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- GBDC
- Stock Information
- Founded
- RARE 2010
- GBDC 2009
- Country
- RARE United States
- GBDC United States
- Employees
- RARE N/A
- GBDC N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- GBDC Finance: Consumer Services
- Sector
- RARE Health Care
- GBDC Finance
- Exchange
- RARE Nasdaq
- GBDC Nasdaq
- Market Cap
- RARE 3.5B
- GBDC 4.0B
- IPO Year
- RARE 2014
- GBDC 2010
- Fundamental
- Price
- RARE $39.91
- GBDC $14.71
- Analyst Decision
- RARE Strong Buy
- GBDC Buy
- Analyst Count
- RARE 15
- GBDC 4
- Target Price
- RARE $90.53
- GBDC $15.50
- AVG Volume (30 Days)
- RARE 1.1M
- GBDC 1.5M
- Earning Date
- RARE 07-31-2025
- GBDC 08-04-2025
- Dividend Yield
- RARE N/A
- GBDC 10.56%
- EPS Growth
- RARE N/A
- GBDC N/A
- EPS
- RARE N/A
- GBDC 1.18
- Revenue
- RARE $590,689,000.00
- GBDC $830,269,000.00
- Revenue This Year
- RARE $18.94
- GBDC $21.93
- Revenue Next Year
- RARE $28.93
- GBDC N/A
- P/E Ratio
- RARE N/A
- GBDC $12.47
- Revenue Growth
- RARE 33.46
- GBDC 28.08
- 52 Week Low
- RARE $29.59
- GBDC $12.68
- 52 Week High
- RARE $60.37
- GBDC $16.08
- Technical
- Relative Strength Index (RSI)
- RARE 65.02
- GBDC 52.06
- Support Level
- RARE $35.51
- GBDC $14.23
- Resistance Level
- RARE $38.19
- GBDC $14.80
- Average True Range (ATR)
- RARE 1.58
- GBDC 0.28
- MACD
- RARE 0.20
- GBDC 0.00
- Stochastic Oscillator
- RARE 98.43
- GBDC 81.69
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.